In particular, 177Lu-PSMA-I&T has been reported to show safety, pharmacokinetics, and tumor uptake comparable to 177Lu-PSMA-617 in patients with CRPC, and to prolong the prognosis of HSPC patients with oligometastasis in a small case randomized trial [54]. Here, FOLH1 is linked to neoplasm.